PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator


When taking a new drug, most patients’ chief concern is
whether or not that drug is going to have the intended effect. They aren’t
always thinking about what other drugs they might already be taking, and how
those drugs could be affected by the new one.

According to the FDA, “Drug-drug interactions occur when two or more drugs react with each other,” which may result in an unexpected side effect. An example that they offer of this is how taking a sedative at the same time as an allergy medication could result in slowing your reactions and making it dangerous to operate a car or machinery.  

Drug-drug interactions, or DDIs, are a serious issue that affect an alarmingly high number of people. While we undoubtedly need to see more comprehensive studies on the problem, those that exist point to DDIs being very prevalent. For instance, this study focused on elderly cancer patients found an average of 2.2 DDIs per patient.

Predictive analytical tools can be a major help in addressing
drug-drug interactions and the adverse drug reactions (ADRs) that can result.
In fact, just recently, Elsevier announced a collaboration with a number of
evaluation partners that include industry leaders – Eli Lilly, Boehringer
Ingelheim, Sanofi, Servier and others – to develop a new and improved drug-drug
interaction risk calculator (DDIRC).

Elsevier’s PharmaPendium team is working with these pharma companies on a DDIRC capable of analyzing both internal and external data. “By enabling pharmaceutical companies to upload internal data, combined with the high-quality, public FDA/EMA data available in PharmaPendium, the new DDIRC will feature increased predictive power,” stated the press release announcing the collaboration.

The project is a perfect fit for Elsevier, as it gives us the
opportunity to leverage our expertise and draw from our high-quality data to
take on one of the most pressing issues in the pharmaceutical and healthcare
industries. We look forward to further opportunities like this to demonstrate
the predictive power of data analytics.

Find out more about another recent industry collaboration, between Elsevier and the FDA, on a drug-induced liver injury (DILI) tool here.

Would you like to learn more about DDI prediction? Get in
touch with me at


Leave a Reply

Your email address will not be published. Required fields are marked *